

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI

## CHARMACY PHARMACEUTICAL CO., LTD.

創美藥業股份有限公司

(A joint stock limited liability company established in the People's Republic of China)

(Stock Code: 2289)

### POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 6 JUNE 2022

References are made to the notice of the extraordinary general meeting of Charmacy Pharmaceutical Co., Ltd. (the "Company") dated 19 May 2022 (the "Notice of EGM") and the circular of the Company dated 19 May 2022 (the "Circular"). Terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

#### POLL RESULTS OF THE EGM

The Board is pleased to announce that all the resolutions proposed as set out in the Notice of EGM were duly passed by the Shareholders by way of poll at the EGM.

The poll results in respect of all the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		Number of votes cast and percentage of total number of votes cast (%)		
		For	Against	Abstain
1.	THAT the framework contract dated 11 April 2022 (the "Framework Sales Agreement") entered into between the Company and Jiangxi Jiangzhong Yishang Operation Co., Ltd.* (江西江中醫藥商業運營有限責任公司) ("Jiangxi Yishang") for the sales of medicines, medical devices, healthcare products and food for which the Company and its subsidiaries (the "Group") act as a distributor which purchase products directly from pharmaceutical manufacturers or their pharmaceutical distributor companies (regardless of whether it has obtained an exclusive distribution right or not) (the "Primary Distributor") to Jiangxi Yishang and its subsidiaries (the "Jiangxi Yishang Group") and the proposed annual caps for the transactions contemplated thereunder, be and are hereby approved and confirmed;	61,158,500 (100%)	0 (0%)	0 (0%)

2.	THAT the framework contract dated 11 April 2022 (the “ <b>Framework Purchases Agreement</b> ”) entered into between the Company and Jiangxi Yishang for the purchase of medicines, medical devices, healthcare products and food for which the Jiangzhong Yishang Group acts as a Primary Distributor from the Jiangzhong Yishang Group and the proposed annual caps for the transactions contemplated thereunder, be and are hereby approved and confirmed; and	61,158,500 (100%)	0 (0%)	0 (0%)
3.	THAT any one director of the Company be and is hereby authorised to sign or execute such other documents or supplemental agreements or deeds on behalf of the Company and to do all such things and take all such actions as he/she may consider necessary or desirable for the purpose of giving effect to the Framework Agreements and completing the transactions contemplated thereunder with such changes as he/she may consider necessary, desirable or expedient.	61,158,500 (100%)	0 (0%)	0 (0%)

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 3, these resolutions were duly passed as ordinary resolutions of the Company.

**Notes:**

1. As at the date of the EGM, the total number of issued Shares was 108,000,000 Shares, comprising 28,000,000 H Shares and 80,000,000 Domestic Shares, which represented the total number of Shares entitling the holders to attend and vote on the proposed resolutions at the EGM.
2. Except for Jiangzhong Yishang (in respect of 29,050,000 Domestic Shares) which was required to abstain from voting in relation to the above resolutions, there were no Shares entitling the holders to attend and abstain from voting in favour of any of the proposed resolutions at the EGM pursuant to Rule 13.40 of the Listing Rules, nor were there any Shareholders who were required under the Listing Rules to abstain from voting at the EGM.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the EGM.
4. For the above resolutions, the Shareholders, proxies or authorised representatives holding in aggregate of 61,158,500 Shares, representing approximately 56.63% of the total voting Shares, were present in person or by proxy at the EGM.
5. Pursuant to the Listing Rules, SHINEWING Certified Public Accountants (LLP), the auditors of the Company for the year 2022, was appointed as the scrutineer at the EGM for the purpose of vote-taking.
6. The attendance record of the Directors at the EGM was as follows:
  - Mr. Yao Chuanglong, Ms. Zheng Yuyan and Mr. Yan Jingbin attended in person; and
  - Mr. Li Weisheng, Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian attended by electronic means.

By order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yao Chuanglong**  
*Chairman*

Shantou, the PRC, 6 June 2022

*As at the date of this announcement, the executive Directors of the Company are Mr. Yao Chuanglong and Ms. Zheng Yuyan; the non-executive Directors of the Company are Mr. Li Weisheng and Mr. Yan Jingbin; and the independent non-executive Directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian(also known as Guan Suzhe) .*

*\* For identification purpose only*